

Specialised Endocrinology Services (Adult) Quality Dashboard 2019/20

Indicator Reference Number	Domain	Theme	Rationale	Measure	Indicator Name /Description	Numerator	Denominator	Period Type	Frequency	Data Source Numerator	Data Source Denominator	Target	Interpretation Guidance	Notes	Reporting Periods			
															Q1	Q2	Q3	Q4
END08c	Domain 4: Ensuring that people have a positive experience of care.	Process		Length of Stay	Mean length of stay (LOS) in days following Pituitary surgery for Cushing's	Length of stay (in days) following procedure (excluding ITU days)	Number of patients having Pituitary surgery for Cushing's, within the reporting period	Rolling Annual	Quarterly	Provider submitted data	Provider submitted data		Lower is better	Note: The CRG have confirmed for the denominator include procedure code B041 for ALL pituitary operations and Primary diagnosis D352 (benign neoplasm of pituitary gland) AND Secondary Diagnosis E240 (Cushing's) for ALL pituitary diagnoses.	Jul 18 - Jun 19	Oct 18 - Sep 19	Jan 19 - Dec 19	Apr 19 - Mar 20
END18	Domain 4: Ensuring that people have a positive experience of care.	Outcome measure		Transition	Proportion of paediatric patients leaving the paediatric service seen by the adult endocrinology team prior to transfer to adult services	Of those in the denominator, the number of patients seen by the adult endocrinology team prior to transfer to adult services	The total number of paediatric patients leaving the paediatric service and transferred to the adult service in the reporting period	Quarterly	Quarterly	Provider submitted data	Provider submitted data		Higher is better		Apr 19 - Jun 19	Jul 19 - Sep 19	Oct 19 - Dec 19	Jan 20 - Mar 20
END21	Domain 4: Ensuring that people have a positive experience of care.	Process measure		MDT	Proportion of new patients with neuroendocrine tumours discussed at MDT	Of those in the denominator, the number of patients discussed at MDT	The total number of new patients with neuroendocrine tumours in the reporting period	Quarterly	Quarterly	Provider submitted data	Provider submitted data		Higher is better		Apr 19 - Jun 19	Jul 19 - Sep 19	Oct 19 - Dec 19	Jan 20 - Mar 20
END22	Domain 4: Ensuring that people have a positive experience of care.	Process measure		MDT	Proportion of new pituitary patients discussed at the MDT meeting	Of those in the denominator, the number of patients discussed at MDT	The total number of new pituitary patients in the reporting period	Quarterly	Quarterly	Provider submitted data	Provider submitted data		Higher is better	Hyperprolactinaemia is defined as greater than 3000 mU/L Include all microadenomata	Apr 19 - Jun 19	Jul 19 - Sep 19	Oct 19 - Dec 19	Jan 20 - Mar 20
END23	Domain 3: Helping people to recover from episodes of ill health or following injury.	Process measure		Waiting time to surgery	Mean time (in days) from patient agreeing to surgery to pituitary surgery being undertaken (Cushing's, pituitary visual compression & pituitary bleeding)	Total sum of all days from patient agreeing to surgery to pituitary surgery in reporting period	The total number of patients having pituitary surgery (Cushing's, pituitary visual compression & pituitary bleeding) in the reporting period	Quarterly	Quarterly	Provider submitted data	Provider submitted data		Lower is better		Apr 19 - Jun 19	Jul 19 - Sep 19	Oct 19 - Dec 19	Jan 20 - Mar 20
END24	Domain 3: Helping people to recover from episodes of ill health or following injury.	Process measure		Length of Stay	Mean length of stay (LOS) in days following non-cancer Adrenal surgery (excluding ITU days)	Mean length of stay (LOS) in days following non-cancer Adrenal surgery	The total number of patients having non-cancer Adrenal surgery in reporting period	Quarterly	Quarterly	Provider submitted data	Provider submitted data		Lower is better	Exclude ITU days	Apr 19 - Jun 19	Jul 19 - Sep 19	Oct 19 - Dec 19	Jan 20 - Mar 20
END26	Domain 3: Helping people to recover from episodes of ill health or following injury.	Outcome measure		Remission	Proportion of patients with Cushing's Disease due to micro adenoma achieving biochemical remission as defined by a post-operative 0900h serum cortisol off steroids of <50nmol/L within 14 days of pituitary surgery.	Of those in the denominator, the number of patients achieving biochemical remission within 14 days of surgery	The total number of patients having Pituitary surgery for Cushing's due to micro adenoma in reporting period	Quarterly	Quarterly	Provider submitted data	Provider submitted data		Higher is better		Apr 19 - Jun 19	Jul 19 - Sep 19	Oct 19 - Dec 19	Jan 20 - Mar 20
END27	Domain 3: Helping people to recover from episodes of ill health or following injury.	Outcome measure		Remission	Proportion of patients with Cushing's Disease due to macro adenoma achieving biochemical remission as defined by a post-operative 0900h serum cortisol <50nmol/L within 14 days of pituitary surgery	Of those in the denominator, the number of patients achieving biochemical remission within 14 days of surgery	The total number of patients having Pituitary surgery for Cushing's due to macro adenoma in reporting period	Quarterly	Quarterly	Provider submitted data	Provider submitted data		Higher is better		Apr 19 - Jun 19	Jul 19 - Sep 19	Oct 19 - Dec 19	Jan 20 - Mar 20

Specialised Endocrinology Services (Adult) Quality Dashboard 2019/20



Indicator Reference Number	Domain	Theme	Rationale	Measure	Indicator Name /Description	Numerator	Denominator	Period Type	Frequency	Data Source Numerator	Data Source Denominator	Target	Interpretation Guidance	Notes	Reporting Periods			
															Q1	Q2	Q3	Q4
END28	Domain 3: Helping people to recover from episodes of ill health or following injury.	Outcome measure		Remission	Proportion of patients with Acromegaly due to micro adenoma achieving disease remission as assessed by normal age-adjusted serum IGF1 or suppressed GH <1ug/L on an OGTT (off both medical therapy) within 4 months of pituitary surgery	Of those in the denominator, the number of patients achieving disease remission as assessed by normal age-adjusted serum IGF1 or suppressed GH <1ug/L on an OGTT (off both medical therapy) within 4 months of surgery	The total number of patients with Acromegaly due to micro adenoma having Pituitary surgery in reporting period	Quarterly	Quarterly	Provider submitted data	Provider submitted data		Higher is better		Apr 19 - Jun 19	Jul 19 - Sep 19	Oct 19 - Dec 19	Jan 20 - Mar 20
END29	Domain 3: Helping people to recover from episodes of ill health or following injury.	Outcome measure		Remission	Proportion of patients with Acromegaly due to macro adenoma achieving disease remission as assessed by normal age-adjusted serum IGF1 or suppressed GH <1ug/L on an OGTT (off both medical therapy) within 4 months of pituitary surgery	Of those in the denominator, the number of patients achieving disease remission as assessed by normal age-adjusted serum IGF1 or suppressed GH <1ug/L on an OGTT (off both medical therapy) within 4 months of surgery	The total number of patients with Acromegaly due to macro adenoma having Pituitary surgery in reporting period	Quarterly	Quarterly	Provider submitted data	Provider submitted data		Higher is better		Apr 19 - Jun 19	Jul 19 - Sep 19	Oct 19 - Dec 19	Jan 20 - Mar 20
END30	Domain 5: Treating and caring for people in a safe environment; and protecting them from avoidable harm.	Outcome measure		Follow up	Proportion of patients under follow up in last year with chronic hypoparathyroidism	Of those in the denominator, the number of patients who have been seen as a follow up patient in the last year	The total number of patients with chronic hypoparathyroidism on caseload for at least a year in reporting period	Quarterly	Quarterly	Provider submitted data	Provider submitted data		Higher is better		Apr 19 - Jun 19	Jul 19 - Sep 19	Oct 19 - Dec 19	Jan 20 - Mar 20
END31	Domain 3: Helping people to recover from episodes of ill health or following injury.	Outcome measure		Serum calcium level	Proportion of patients with chronic hypoparathyroidism with adjusted serum calcium measured in range 2.0 – 2.3 mmol/L	Of those in the denominator, the number of patients who measured in range 2.0 - 2.3 mmol/L	The total number of patients with chronic hypoparathyroidism with adjusted serum calcium measured in reporting period	Quarterly	Quarterly	Provider submitted data	Provider submitted data		Higher is better		Apr 19 - Jun 19	Jul 19 - Sep 19	Oct 19 - Dec 19	Jan 20 - Mar 20
END33	Domain 3: Helping people to recover from episodes of ill health or following injury.	Outcome measure		PHPT	Proportion of patients with PHPT with adjusted serum calcium within reference range 6 months following first parathyroid surgery	Of those in the denominator, the number of patients who had Primary hyperparathyroidism (PHPT) and with serum adjusted Ca within reference range 6 months following surgery	The total number of patients having first time parathyroid surgery in the reporting period	Quarterly	Quarterly	Provider submitted data	Provider submitted data		Higher is better	Reference range for calcium 2.20 – 2.60	Apr 19 - Jun 19	Jul 19 - Sep 19	Oct 19 - Dec 19	Jan 20 - Mar 20
END34	Domain 3: Helping people to recover from episodes of ill health or following injury.	Outcome measure		PHPT	Proportion of patients with PHPT with adjusted serum calcium within reference range 6 months following second parathyroid surgery	Of those in the denominator, the number of patients who had Primary hyperparathyroidism (PHPT) and with serum adjusted Ca within reference range 6 months following surgery	The total number of patients having second time parathyroid surgery in the reporting period	Quarterly	Quarterly	Provider submitted data	Provider submitted data		Higher is better	Reference range for calcium 2.20 – 2.60	Apr 19 - Jun 19	Jul 19 - Sep 19	Oct 19 - Dec 19	Jan 20 - Mar 20
END35	Domain 3: Helping people to recover from episodes of ill health or following injury.	Outcome measure		Turners Syndrome	Proportion of patients with Turners Syndrome who have had a cardiac MRI or transthoracic echo within the last 5 years	Of those in the denominator, the number who have had a cardiac MRI or transthoracic echo in the last 5 years	The total number of patients with Turner's Syndrome on caseload (for at least 5 years) in the reporting period	Quarterly	Quarterly	Provider submitted data	Provider submitted data		Higher is better		Apr 19 - Jun 19	Jul 19 - Sep 19	Oct 19 - Dec 19	Jan 20 - Mar 20
END36	Domain 5: Treating and caring for people in a safe environment; and protecting them from avoidable harm.	Process measure		Clinical Trial	Proportion of patients recruited to a clinical trial	Of those in the denominator, the number who are recruited to a clinical trial	The total number of specialised endocrine patients on caseload in the reporting period	Quarterly	Quarterly	Provider submitted data	Provider submitted data		Neutral	to include natural history studies	Apr 19 - Jun 19	Jul 19 - Sep 19	Oct 19 - Dec 19	Jan 20 - Mar 20

Data collection has been approved by the Review of Central Returns - ROCR
ROCR/OR/2230/001MAND